<DOC>
	<DOCNO>NCT02532569</DOCNO>
	<brief_summary>A multi-center , open , phase 4 clinical trial ass long-term immunogenicity safety fourth administration Boryung Cell-Culture Japanese Encephalitis Vaccine inj . conduct exploratory investigation vaccine interchangeability Korean child age 6 year receive primary 3 dos ENCEVAC® Japanese Encephalitis Vaccine-GCC® inj .</brief_summary>
	<brief_title>Long-term Immunogenicity Safety Fourth Administration Boryung Cell-Culture Japanese Encephalitis Vaccineinj</brief_title>
	<detailed_description>This follow-up study KD287-BR-CT-301 ( ClinicalTrials.gov identifier : NCT01150942 ) , phase 3 study investigate efficacy safety cell-culture Japanese encephalitis vaccine ( ENCEVAC® ) compare mouse brain-derived Japanese encephalitis vaccine ( Japanese Encephalitis vaccine-GCC® inj ) . Subjects participate KD287-BR-CT-301 study receive 3 dos Japanese encephalitis vaccine ( JEV ) assign randomization age 12 month subject complete 3 dos JEV target population study . The purpose study investigate long-term immunogenicity safety booster ( fourth ) dose JEV , give Boryung Cell-Culture Japanese Encephalitis Vaccine inj , proven ENCEVAC® manufacture different manufacturer .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parent/guardian ( legally authorize representative ) give voluntary write consent subject 's participation fully inform purpose , method , risk , benefit study . Male female child complete primary 3 dos JEV KD287BRCT301study . Male female child reach least 6 year age day booster dose JEV . Male female child identify healthy base physical examination medical history . Children acute febrile illness tympanic temperature ≥38.0 ℃ day booster dose JEV . Children moderate severe acute disease ( regardless fever ) . Children history encephalitis , encephalopathy , cerebromeningitis , convulsion . Children receive JEV ( include live JEV ) investigational product administer KD287BRCT301study . Children fever ( ≥ 40 °C ) systemic allergy within 48 hour vaccination . Children show anaphylactic reaction investigational product administer KD287BRCT301study likely allergic ingredient investigational product . Children diagnose immunodeficiency acquire immune deficiency family history immunodeficiency . Children receive vaccine within 28 day booster dose JEV ( vaccine administer accord national vaccination program . Children receive immunosuppressive therapy within 28 day booster dose JEV . There possibility immune globulin preparation excrete enough day booster dose JEV child receive product . Children currently participate plan participate clinical study study period . Other ineligible condition judge discretion principal investigator subinvestigators .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>